Cargando…

Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34

BACKGROUND: Preoperative chemotherapy containing anthracyclines and taxanes is well established in early-stage breast cancer. Previous studies have suggested that the chemotherapy sequence may matter but definitive evidence is missing. ABCSG trial 34 evaluated the activity of the MUC1 vaccine tecemo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bartsch, Rupert, Singer, Christian F., Pfeiler, Georg, Hubalek, Michael, Stoeger, Herbert, Pichler, Angelika, Petru, Edgar, Bjelic-Radisic, Vesna, Greil, Richard, Rudas, Margaretha, Muy-Kheng, Tea Maria, Wette, Viktor, Petzer, Andreas L., Sevelda, Paul, Egle, Daniel, Dubsky, Peter C., Filipits, Martin, Fitzal, Florian, Exner, Ruth, Jakesz, Raimund, Balic, Marija, Tinchon, Christoph, Bago-Horvath, Zsuzsanna, Frantal, Sophie, Gnant, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144560/ https://www.ncbi.nlm.nih.gov/pubmed/33762716 http://dx.doi.org/10.1038/s41416-021-01284-2

Ejemplares similares

PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2– disease: results from 1204 patients in the randomized ABCSG-8 trial
por: Fitzal, F, et al.
Publicado: (2021)

Independent validation of stromal uPA in ABCSG-08: Level 1b evidence for the prognostic value of uPA immunohistochemistry
por: Singer, C.F., et al.
Publicado: (2022)

Primary surgery versus no surgery in synchronous metastatic breast cancer: patient-reported quality-of-life outcomes of the prospective randomized multicenter ABCSG-28 Posytive Trial
por: Bjelic-Radisic, V., et al.
Publicado: (2020)

The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial
por: Gnant, M, et al.
Publicado: (2013)

ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6
por: Filipits, M., et al.
Publicado: (2021)

The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER(+), HER2(−) early breast cancer
por: Exner, R, et al.
Publicado: (2014)

Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients
por: Wimmer, Kerstin, et al.
Publicado: (2023)

A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohort
por: Dubsky, P., et al.
Publicado: (2020)

Effect of concomitant statin treatment in postmenopausal patients with hormone receptor-positive early-stage breast cancer receiving adjuvant denosumab or placebo: a post hoc analysis of ABCSG-18
por: Minichsdorfer, C., et al.
Publicado: (2022)

The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial
por: Fitzal, F, et al.
Publicado: (2015)

Efficacy of tamoxifen±aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial
por: Pfeiler, G, et al.
Publicado: (2013)

Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response
por: Zhou, Qing, et al.
Publicado: (2022)

Objective breast symmetry analysis with the breast analyzing tool (BAT): improved tool for clinical trials
por: Krois, Wilfried, et al.
Publicado: (2017)

Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer
por: Pfeiler, G, et al.
Publicado: (2013)

Impact of Imaging-Guided Localization on Performance of Tailored Axillary Surgery in Patients with Clinically Node-Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)
por: Weber, Walter P., et al.
Publicado: (2023)

Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases
por: Bartsch, R, et al.
Publicado: (2012)

Prognostic impact of breast cancer subtypes in elderly patients
por: Bergen, E. S., et al.
Publicado: (2016)

Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)()
por: Weber, Walter P., et al.
Publicado: (2021)

Estrogen Receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term Outcome in Postmenopausal Patients with Endocrine-Responsive Early Breast Cancer
por: Singer, Christian F., et al.
Publicado: (2022)

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer
por: Dubsky, P., et al.
Publicado: (2013)

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients
por: Dubsky, P, et al.
Publicado: (2013)

Brain metastases free survival differs between breast cancer subtypes
por: Berghoff, A, et al.
Publicado: (2012)

Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens
por: Tendl-Schulz, Kristina A., et al.
Publicado: (2020)

Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)
por: Tausch, Christoph, et al.
Publicado: (2023)

Interphase cytogenetics reveals a high incidence of aneuploidy and intra-tumour heterogeneity in breast cancer.
por: Fiegl, M., et al.
Publicado: (1995)

Optimal duration of adjuvant endocrine therapy: how to apply the newest data
por: Wimmer, Kerstin, et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients
por: Blank, Patricia R., et al.
Publicado: (2014)

More is not always better—what can be learned from the D-CARE trial
por: Pfeiler, Georg, et al.
Publicado: (2020)

Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2− advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT
por: Steger, Guenther G., et al.
Publicado: (2020)

Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer
por: Bartsch, Rupert, et al.
Publicado: (2009)

Targeted Therapy in HR+ HER2− Metastatic Breast Cancer: Current Clinical Trials and Their Implications for CDK4/6 Inhibitor Therapy and beyond Treatment Options
por: Elfgen, Constanze, et al.
Publicado: (2021)

Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
por: Gampenrieder, Simon Peter, et al.
Publicado: (2021)

Neutrophil/Lymphocyte ratio has no predictive or prognostic value in breast cancer patients undergoing preoperative systemic therapy
por: Suppan, Christoph, et al.
Publicado: (2015)

Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
por: Rinnerthaler, Gabriel, et al.
Publicado: (2022)

Patients’ view of routine follow-up after breast cancer treatment
por: Bjelic-Radisic, Vesna, et al.
Publicado: (2017)

St. Gallen/Vienna 2021: A Brief Summary of the Consensus Discussion on Customizing Therapies for Women with Early Breast Cancer
por: Thomssen, Christoph, et al.
Publicado: (2021)

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
por: Sestak, Ivana, et al.
Publicado: (2019)

Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy
por: Exner, Ruth, et al.
Publicado: (2016)

Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancer
por: Marhold, Maximilian, et al.
Publicado: (2023)

Influence of a Structured Exercise Training on Patients Reported Quality of Life in Colorectal Cancer Patients After Adjuvant Chemotherapy: A Pilot Study
por: Piringer, Gudrun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_01msn7t6319fdj3su1ji6pkck5